• Publications
  • Influence
A Mass Spectrometric-Derived Cell Surface Protein Atlas
Cell surface proteins are major targets of biomedical research due to their utility as cellular markers and their extracellular accessibility for pharmacological intervention. However, informationExpand
  • 149
  • 6
  • PDF
On the development of plasma protein biomarkers.
The development of plasma biomarkers has proven to be more challenging than initially anticipated. Many studies have reported lists of candidate proteins rather than validated candidate markers withExpand
  • 262
  • 5
Direct selection of antibodies from complex libraries with the protein fragment complementation assay.
The aim of the present study was to develop the protein fragment complementation assay (PCA) for the intracellular selection of specific binding molecules from the fully synthetic HuCAL antibodyExpand
  • 55
  • 5
  • PDF
Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome.
BACKGROUND Metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor outcome. Prognostic information is useful and aids treatment decisions. However, current nomograms basedExpand
  • 41
  • 5
PASSEL: The PeptideAtlas SRMexperiment library
TLDR
The PeptideAtlas SRM Experiment Library (PASSEL) allows researchers to easily submit proteomic data sets generated by SRM. Expand
  • 165
  • 4
A DNA-Damage Selective Role for BRCA1 E3 Ligase in Claspin Ubiquitylation, CHK1 Activation, and DNA Repair
BACKGROUND The breast and ovarian cancer suppressor BRCA1 is essential for cellular responses to DNA damage. It heterodimerizes with BARD1 to acquire an E3 ubiquitin (Ub) ligase activity that isExpand
  • 45
  • 4
Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer
A key barrier to the realization of personalized medicine for cancer is the identification of biomarkers. Here we describe a two-stage strategy for the discovery of serum biomarker signaturesExpand
  • 118
  • 3
  • PDF
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).
BACKGROUND There is evidence linking metformin to improved prostate cancer (PCa)-related outcomes. OBJECTIVE To evaluate treatment with metformin in patients with castration-resistant PCa (CRPC)Expand
  • 75
  • 3
  • PDF
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).
BACKGROUND The phosphatase and tensin homolog (PTEN) tumor suppressor gene is deregulated in many advanced prostate cancers, leading to activation of the phosphatidylinositol 3-kinaseExpand
  • 100
  • 2
Comprehensive description of the N-glycoproteome of mouse pancreatic β-cells and human islets.
Cell surface N-glycoproteins provide a key interface of cells to their environment and therapeutic entry points for drug and biomarker discovery. Their comprehensive description denotes therefore aExpand
  • 28
  • 2